Euglycemic DKA (euDKA) as a presentation of COVID-19.

Bhagwan DassAndrew BeckCody HolmesGlenville Morton

Published in: Clinical case reports (2020)

COVID-19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
liver failure
prognostic factors
intensive care unit
respiratory failure
patient reported outcomes